Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.50 |
| ▸ | MIF | P14174 | 11/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | GLA | P06280 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048148 | 0.94 | HSD17B3 (0.58) | HSD17B3ESR2MIFMEN1KMT2A | |
| SCHEMBL3273965 | 0.79 | STS (0.48) | MEN1KMT2AKDM4EGLAGAA | |
| SCHEMBL15961994 | 0.78 | HSD17B3 (0.63) | HSD17B3ESR2MIFMEN1KMT2A | |
| Phosphoric Acid SCHEMBL6259521 | 0.77 | HSD17B3 (0.87) | HSD17B3ESR2MIFMEN1KMT2A | |
| SCHEMBL23041007 | 0.75 | HSD17B3 (0.58) | HSD17B3ESR2MIFMEN1KMT2A | |
| SCHEMBL19480350 | 0.73 | HSD17B3 (0.56) | HSD17B3ESR2MIFMEN1KMT2A | |
| SCHEMBL9436011 | 0.73 | MIF (0.60) | HSD17B3ESR2MIFMEN1KMT2A | |
| SCHEMBL620973 | 0.73 | HPGD (0.55) | ESR2KDM4EGLAGAAALDH1A1 | |
| Umbelliferone SCHEMBL2246676 | 0.73 | CA9 (0.85) | HSD17B3ESR2MEN1KMT2AKDM4E | |
| SCHEMBL10794401 | 0.73 | HSD17B3 (0.64) | HSD17B3ESR2MIFMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399213-B2 | Method for monitoring intracellular tyrosine phosphatase activity | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2013-03-19 | — | — | US | disclosed |
| WO-2010039899-A2 | METHOD FOR MONITORING INTRACELLULAR TYROSINE PHOSPHATASE ACTIVITY | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20100086957-A1 | METHOD FOR MONITORING INTRACELLULAR TYROSINE PHOSPHATASE ACTIVITY | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100086957-A1 | METHOD FOR MONITORING INTRACELLULAR TYROSINE PHOSPHATASE ACTIVITY | PTPRCAP, PTPRC, PTPA | HSD17B3 4181/4885ESR2 4643/4885MIF 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.